ArticleClinical pharmacokinetics2021

Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.

Fredrik Jonsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.